tldrdaily.news logo

Johnson & Johnson's Bold Growth Strategy: 20 New Drugs, 6% Sales Growth, and Key Long Term Drivers

1 min read
Source: Endpoints News
Johnson & Johnson's Bold Growth Strategy: 20 New Drugs, 6% Sales Growth, and Key Long Term Drivers
Photo: Endpoints News
TL;DR Summary

Johnson & Johnson has unveiled its drug development plans, projecting billions of dollars in added sales from new drugs in cancer, immunology, and other areas, including high-risk bets in Alzheimer's disease. The company aims for drug sales to grow 5% to 7% annually from 2025 to 2030, with 20 new drugs and 50 expanded products, including 10 with peak sales of $5 billion or more.

Topics:business#alzheimers-disease#cancer#drug-development#johnson-and-johnson#pharmaceuticals#sales-projections
Share this article
  1. J&J promises 20 new drugs to back pharma growth through end of decade, as John Reed shares his plans  Endpoints News
  2. Johnson & Johnson forecasts as much as 6% sales growth in 2024  Yahoo Finance
  3. Johnson & Johnson MedTech outlines future growth plans  Mass Device
  4. As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth  FiercePharma
  5. Johnson & Johnson (NYSE:JNJ) Shares Key Long Term Growth Drivers  TipRanks
  6. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

2

Time Saved

0 min

vs 1 min read

Condensed

55%

144 → 65 words

Want the full story? Read the original article

Read on Endpoints News